Inhibitor Therapeutics, Inc. has provided a significant update regarding its ongoing pharmacokinetic (PK) clinical program aimed at treating basal cell carcinomas in patients with Gorlin Syndrome. The company announced plans to file a new global patent application for its proprietary itraconazole formulation, which is designed to enhance solubility and absorption, addressing the limitations of the conventional crystalline form of the drug. The comparative PK study is currently underway in Malaysia and is expected to yield results that will support the company's regulatory strategy under the FDA’s 505(b)(2) pathway. The study is progressing as planned, with key milestones set for April 2026. This update is expected to positively influence the company's stock price as it demonstrates progress in a critical area of their pipeline, potentially leading to a New Drug Application (NDA) submission in the near future.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.